{"id":"neisvac-ctm","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Irritability"},{"rate":"5-10","effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL1224646","moleculeType":"Small molecule","molecularWeight":"316.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsular material from N. meningitidis serogroup C conjugated to a protein carrier, which enhances immunogenicity and promotes T-cell dependent immune responses. This results in the production of protective antibodies that prevent meningococcal disease caused by serogroup C strains.","oneSentence":"NeisVac-C is a meningococcal C conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:45.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroup C in infants, children, and adults"}]},"trialDetails":[{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT00891176","phase":"PHASE3","title":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-14","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":582}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NeisVac-CTM","genericName":"NeisVac-CTM","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"NeisVac-CTM is a vaccine used to protect against Neisseria Meningitidis, Haemophilus Influenzae Type b, and other infections. It is a small molecule vaccine, although the exact formulation is not specified in the provided facts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}